Premium
Validated quantitation method for a peptide in rat serum using liquid chromatography/high‐field asymmetric waveform ion mobility spectrometry
Author(s) -
Klaassen Tobias,
Szwandt Simon,
Kapron James T.,
Roemer Axel
Publication year - 2009
Publication title -
rapid communications in mass spectrometry
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.528
H-Index - 136
eISSN - 1097-0231
pISSN - 0951-4198
DOI - 10.1002/rcm.4147
Subject(s) - chemistry , bioanalysis , ion mobility spectrometry , chromatography , ion suppression in liquid chromatography–mass spectrometry , peptide , mass spectrometry , matrix (chemical analysis) , fragmentation (computing) , tandem mass spectrometry , selectivity , liquid chromatography–mass spectrometry , analytical chemistry (journal) , biochemistry , computer science , catalysis , operating system
The analysis of peptides presents serious challenges for bioanalytical scientists including low total ion current and non‐selective fragmentation during tandem mass spectrometry (MS/MS). During method validation of a peptide in rat serum matrix some interferences could not be easily removed and thus prevented accurate and precise measurement. These problems associated with peptide quantitation were resolved by using FAIMS (high‐Field Asymmetric waveform Ion Mobility Spectrometry). This selectivity‐enhancing technique filters out matrix interferences, and the resulting pseudo‐selected reaction monitoring (pseudo‐SRM) chromatograms were nearly free from interferences. Control blank matrix samples contained an acceptable level of interference (only 7% signal as compared to the lower level of quantitation). Chromatographic peaks were easily, accurately and precisely integrated resulting in a validated liquid chromatography (LC)/FAIMS‐MS/MS method for the analysis of a peptide drug in rat serum according to United States Food and Drug Administration (US FDA) bioanalytical guidelines. These results confirm that new selectivity‐enhancing technologies aid the pharmaceutical industry in reliably producing acceptable pharmacokinetic data. Copyright © 2009 John Wiley & Sons, Ltd.